NASDAQ:DSGN

Design Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DSGN

*Your capital is at risk

$12.18

-0.440 (-3.49%)

At Close: Jul 31, 2026

Design Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -15.46. In total, the insiders bought 16.33M and sold 2.76M DSGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-15.46
● Buy	16.33M shares
● Sell	2.76M shares
92% Buy Activity Moderate Positive Correlation
Buy Signal Medium Confidence Jun 09, 2026 Analysis Breakdown: Weakened by a contradictory negative Insider Power Score. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 13, 2024 Buy	Stock Option (right to buy)	Kim Jae B. Chief Medical Officer	Officer	115 000 Value: $916.6K
Mar 13, 2024 Buy	Stock Option (right to buy)	Kim Jae B. Chief Medical Officer	Officer	175 000 Value: $444.5K
Mar 13, 2024 Buy	Stock Option (right to buy)	Kim Jae B. Chief Medical Officer	Officer	175 000 Value: $444.5K
Mar 13, 2024 Buy	Stock Option (right to buy)	Kim Jae B. Chief Medical Officer	Officer	115 000 Value: $916.6K
Mar 13, 2024 Buy	Stock Option (right to buy)	Kim Jae B. Chief Medical Officer	Officer	315 000 Value: $4.02M
Mar 13, 2024 Buy	Common Stock	Kim Jae B. Chief Medical Officer	Officer	0 Value: $0
Jan 02, 2024 Buy	Stock Option (right to buy) A-Award	Burgess Julie Chief Accounting Officer	Officer	110 000 Value: $279.4K
Jan 02, 2024 Buy	Stock Option (right to buy) A-Award	Jeffries Sean Chief Operating Officer	C-Suite Officer	350 000 Value: $889.0K
Jan 02, 2024 Buy	Stock Option (right to buy) A-Award	Jeffries Sean Chief Operating Officer	C-Suite Officer	350 000 Value: $889.0K
Jan 02, 2024 Buy	Stock Option (right to buy) A-Award	Burgess Julie Chief Accounting Officer	Officer	110 000 Value: $279.4K
Dec 01, 2023 Buy	Stock Option (right to buy) A-Award	Lappe Rodney W Director	Director	69 186 Value: $173.7K
Dec 01, 2023 Buy	Stock Option (right to buy) A-Award	Lappe Rodney W Director	Director	69 186 Value: $173.7K
Dec 01, 2023 Buy	Stock Option (right to buy) A-Award	Ansari Aseem Z. 10 Percent Owner	10% Owner	100 000 Value: $251.0K
Dec 01, 2023 Buy	Stock Option (right to buy) A-Award	Ansari Aseem Z. 10 Percent Owner	10% Owner	100 000 Value: $251.0K
Sep 29, 2023 Buy	Common Stock P-Purchase	Lappe Rodney W Director	Director	21 000 Value: $49.3K
Sep 29, 2023 Buy	Common Stock P-Purchase	Lappe Rodney W Director	Director	21 000 Value: $49.3K
Sep 01, 2023 Buy	Stock Option (right to buy) A-Award	Shah Pratik President, CEO And Chairperson	CEO / President	1 050 000 Value: $2.60M
Mar 30, 2021 Buy	Common Stock C-Conversion	William Arsani Director	Director	814 874 Value: $0
Mar 30, 2021 Buy	Common Stock P-Purchase	William Arsani Director	Director	700 000 Value: $14.0M
Mar 30, 2021 Buy	Common Stock C-Conversion	William Arsani Director	Director	814 874 Value: $0
Mar 30, 2021 Buy	Common Stock C-Conversion	William Arsani Director	Director	1 217 627 Value: $0
Mar 30, 2021 Buy	Common Stock P-Purchase	William Arsani Director	Director	700 000 Value: $14.0M
Mar 30, 2021 Buy	Common Stock C-Conversion	William Arsani Director	Director	1 217 627 Value: $0
Mar 30, 2021 Buy	Common Stock C-Conversion	William Arsani Director	Director	814 874 Value: $0
Mar 30, 2021 Buy	Common Stock P-Purchase	William Arsani Director	Director	700 000 Value: $14.0M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DESIGN THERAPEUTICS, INC.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysf...

Read Full Profile Here